EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Outcomes of Novel Hormonal Therapies in Men With Advanced Prostate Cancer by Treating Specialist

Kassem S Faraj iD, Mary Oerline, Samuel Kaufman, Avinash Maganty iD, Megan E V Caram iD, Vahakn B Shahinian, Brent K Hollenbeck

Cancer Medicine · 2025

DOI: 10.1002/cam4.71219 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Kassem S Faraj und 6 weiteren Autor:innen. Beteiligte Einrichtung: Dow Division of Health Services Research, University of Michigan, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Antineoplastic Agents, Hormonal, Urologists, Oncologists. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

In the past decade, the management of advanced prostate cancer has shifted to novel hormonal therapies. As a result, urologists have increased their involvement in the management of advanced prostate cancer. These therapies require close monitoring due to the possibility of adverse cardiometabolic events. We assessed outcomes among men diagnosed with advanced prostate cancer started on novel hormonal therapy by a urologist compared to those by a medical oncologist.

Methods

We performed a retrospective cohort study of Medicare beneficiaries with advanced prostate cancer treated with a novel hormonal therapy between 2012 and 2019. The primary outcome was an adverse event comprised of a hospital visit for a cardiometabolic event within 6 months of starting a novel hormonal therapy. Secondary outcomes included monthly out‐of‐pocket costs and treatment adherence.

Results

There were 1212 (23%) and 4124 (77%) patients who were prescribed a novel hormonal therapy for the first time by a urologist and medical oncologist, respectively. No difference in the composite adverse event measure was observed in those managed by urologists or medical oncologists (4.2% vs. 4.7%, respectively, p = 0.49). Out‐of‐pocket costs, in men without low‐income subsidies, did not vary by specialty ($772 vs. $790, p = 0.58). Adherence to treatment did not vary in men managed by urologists or medical oncologists (75% vs. 74%, respectively, p = 0.64).

Conclusions

The specialty of the physician prescribing a novel hormonal therapy was not associated with the risk of a cardiometabolic adverse event. Further, management by a urologist did not adversely affect costs to patients or adherence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsAntineoplastic Agents, HormonalUrologistsOncologistsAndrogen AntagonistsHumansMaleRetrospective StudiesAgedAged, 80 and overUnited StatesMedicareTreatment Outcome

Stichwörter der Autor:innen

adverse eventsfinancial toxicityprostate cancerquality

Substanzen

Antineoplastic Agents, HormonalAndrogen Antagonists

Autor:innen und Institutionen

  • Dow Division of Health Services Research, University of Michigan, Ann Arbor, Michigan, USA.
  • VA Health Services Research, Centers for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, Michigan, USA.
  • Division of Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
  • Division of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
  • Department of Urology, Massachusetts General Hospital, Boston, Massachusetts, USA.

ORCID-Profile: Kassem S Faraj, Avinash Maganty, Megan E V Caram

Förderung

  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Faraj, K. S., Oerline, M., Kaufman, S., Maganty, A., Caram, M. E. V., Shahinian, V. B., & Hollenbeck, B. K. (2025). Outcomes of Novel Hormonal Therapies in Men With Advanced Prostate Cancer by Treating Specialist. Cancer Medicine. https://doi.org/10.1002/cam4.71219

Vancouver

Faraj KS, Oerline M, Kaufman S, Maganty A, Caram MEV, Shahinian VB, et al. Outcomes of Novel Hormonal Therapies in Men With Advanced Prostate Cancer by Treating Specialist. Cancer Medicine. 2025. doi:10.1002/cam4.71219

BibTeX
@article{Faraj2025,
  author = {Faraj, Kassem S and Oerline, Mary and Kaufman, Samuel and Maganty, Avinash and Caram, Megan E V and Shahinian, Vahakn B and Hollenbeck, Brent K},
  title = {Outcomes of Novel Hormonal Therapies in Men With Advanced Prostate Cancer by Treating Specialist},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.71219}
}
Kostenlos starten →